Company intelligence / Profile preview

Aomics

Frankfurt, Hessen, Germany

Ownership: Private
Development stage: Other

Overview

Aomics has established over 20 analytic pipelines for clinical data science, supporting over 8 distinct therapeutic areas, primarily in immuno-oncology studies. Their core expertise is in transforming complex clinical datasets into meaningful statistical insights to optimize clinical trial designs and project outcomes for partners in pharma, biotech, CROs, and universities.

Therapeutic areas: OncologyOther
Modalities: Bioinformatics servicesStatistical consultingMachine learning-supported analytics
Industry: Drug Discovery Services

Partnerships

Implied partnerships with pharmaceutical, biotech, CRO, and academic clients, including reference to SolisBiodyne, QIAGEN, BioMerieux, and Eppendorf via management’s previous experience, but no detailed public partnership disclosures

Beyond the preview

Go deeper on Aomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aomics.

Explore the full profile